A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for ...

After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing ...